
---
title: Anti-Asthmatics (INICET Cheatsheet)
markmap:
  colorFreezeLevel: 6
---

# Anti-Asthmatics

## Controllers (Anti-inflammatories) - Baseline Therapy

### ICS (Budesonide, Fluticasone, Beclomethasone)
-   **Mechanism:** Reduce inflammation, mucus, hyperresponsiveness
-   **Use:** First-line for persistent asthma (Step 2+)
-   **SE:** Oral candidiasis, Dysphonia, Cough, (Systemic rare with low dose)
-   **Key Point:** Cornerstone of asthma management

### ICS + LABA Combinations (Symbicort, Seretide, etc.)
-   **Components:** ICS + Formoterol (Rapid onset) OR ICS + Salmeterol/Vilanterol (Slower onset)
-   **Use:** Moderate-severe persistent asthma (Step 3+), **MART** (Maintenance And Reliever Therapy - Budesonide/Formoterol or Beclomethasone/Formoterol)

### Leukotriene Modifiers (Montelukast, Zafirlukast - Receptor Antagonists, Zileuton - Synthesis Inhibitor)
-   **Mechanism:** Block/inhibit leukotriene pathway
-   **Use:** Aspirin-exacerbated asthma, Exercise-induced asthma, Add-on therapy
-   **Buzzword:** Churg-Strauss risk (esp. with steroid withdrawal), Neuropsychiatric events (Montelukast)

### LABA (Salmeterol, Formoterol, Vilanterol)
-   **Mechanism:** Long-acting Beta-2 agonism
-   **Use:** **NEVER** used alone in asthma; **ALWAYS** with ICS (Controller)
-   **Key Point:** Monotherapy linked to increased mortality

### LAMA (Tiotropium, Umeclidinium)
-   **Mechanism:** Long-acting Anticholinergic (M3 blockade)
-   **Use:** Add-on for severe asthma (Step 4/5), Mainstay in COPD

### Oral Corticosteroids (Prednisolone)
-   **Use:** Severe acute exacerbations, Refractory asthma (short courses/low dose maintenance)
-   **SE:** Significant systemic effects (Cushingoid, Osteoporosis, Diabetes, Hypertension)

### Biologics (Monoclonal Antibodies)
-   **Use:** Severe refractory asthma (Phenotype-guided, Step 5+)
-   **Types & Targets:**
    -   Omalizumab: Anti-IgE (Severe Allergic Asthma)
    -   Mepolizumab, Reslizumab: Anti-IL-5 (Severe Eosinophilic Asthma)
    -   Benralizumab: Anti-IL-5R (Severe Eosinophilic Asthma)
    -   Dupilumab: Anti-IL-4R/IL-13R (Severe Eosinophilic/Type 2 Asthma, CRSwNP)
    -   Tezepelumab: Anti-TSLP (Broad severe asthma)

## Relievers (Bronchodilators) - Symptomatic Relief

### SABA (Salbutamol, Terbutaline)
-   **Mechanism:** Short-acting Beta-2 agonism
-   **Use:** Acute symptom relief, Exercise prophylaxis
-   **Key Point:** **Rescue inhaler**. Increased use indicates poor control.

### SAMA (Ipratropium)
-   **Mechanism:** Short-acting Anticholinergic (M3 blockade)
-   **Use:** Add-on in acute severe exacerbation, COPD

### Methylxanthines (Theophylline, Aminophylline IV)
-   **Mechanism:** PDE inhibition, Adenosine antagonism, Histone deacetylation (complex)
-   **Use:** Refractory asthma (less common now), COPD
-   **Buzzword:** **Narrow Therapeutic Index**, Toxicity (Nausea, Vomiting, Arrhythmias, Seizures)

## Acute Exacerbation Management

### Mild/Moderate
-   SABA (frequent doses)
-   Oral Corticosteroids

### Severe/Life-threatening
-   High-dose SABA + SAMA (via nebulizer/MDI+spacer)
-   Oral/IV Corticosteroids
-   Oxygen (target SpO2 93-95%)
-   IV Magnesium Sulfate (Severe/Life-threatening)
-   Consider Ventilation

## Management Strategy

### GINA Stepwise Approach
-   **Principle:** Based on symptom control & exacerbation risk
-   **Cycle:** Assess -> Adjust Treatment -> Review Response

### Key Assessments
-   Symptom Control (Daytime, Nighttime, SABA use, Activity limitation)
-   Exacerbation Risk (History, FEV1, ICS adherence, Comorbidities)
-   Inhaler Technique
-   Adherence

## INICET Buzzwords

### GINA Guidelines
### MART (Maintenance And Reliever Therapy)
### Status Asthmaticus
### FEV1/FVC Ratio
### PEFR (Peak Expiratory Flow Rate)
### Eosinophilic Asthma
### FENO (Fractional Exhaled Nitric Oxide)
### Churg-Strauss Syndrome
### IgE (Omalizumab)
### IL-5 (Mepolizumab, Reslizumab)
### IL-4/IL-13 (Dupilumab)
### Beta-2 Agonist Toxicity
### Theophylline Toxicity
### Aspirin Exacerbated Respiratory Disease (AERD)
